Effect of Fucoidan on the Mitochondrial Membrane Potential (Delta psi m) of Leukocytes from Patients with Active COVID-19 and Subjects That Recovered from SARS-CoV-2 Infection

Fucoidan is a polysaccharide obtained from marine brown algae, with anti-inflammatory, anti-viral, and immune-enhancing properties, thus, fucoidan may be used as an alternative treatment (complementary to prescribed medical therapy) for COVID-19 recovery. This work aimed to determine the ex-vivo effects of treatment with fucoidan (20 mu g/mL) on mitochondrial membrane potential (Delta psi m, using a cationic cyanine dye, 3,3 '-dihexyloxacarbocyanine iodide (DiOC(6)(3)) on human peripheral blood mononuclear cells (HPBMC) isolated from healthy control (HC) subjects, COVID-19 patients (C-19), and subjects that recently recovered from COVID-19 (R1, 40 +/- 13 days after infection). In addition, ex-vivo treatment with fucoidan (20 and 50 mu g/mL) was evaluated on Delta psi m loss induced by carbonyl cyanide 3-chlorophenylhydrazone (CCCP, 150 mu M) in HPBMC isolated from healthy subjects (H) and recovered subjects at 11 months post-COVID-19 (R2, 335 +/- 20 days after infection). Data indicate that SARS-CoV-2 infection induces HPBMC loss of Delta psi m, even 11 months after infection, however, fucoidan promotes recovery of Delta psi m in PBMCs from COVID-19 recovered subjects. Therefore, fucoidan may be a potential treatment to diminish long-term sequelae from COVID-19, using mitochondria as a therapeutic target for the recovery of cellular homeostasis.